LIFE Successful in-vitro quality testing of sensor

13 Jun 2024 14:33 CEST

Bergen, Norway, June 13th, 2024: Today, Lifecare ASA (LIFE), a clinical stage
medical sensor company developing the next generation Continuous Glucose
Monitor (CGM), announces that the company has concluded a successful in-vitro
quality test of sensor for use in longevity study.

Reference is made to stock exchange notification June 10th, 2024. The internal
in-vitro quality test has been successfully conducted.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 19 no. 3. The information was submitted for publication
at 2024-06-13 14:33 CEST.

More information:
Access the news on Oslo Bors NewsWeb site

621461_LIFE Successful in-vitro quality testing of sensor.pdf